Ignite Creation Date:
2025-12-25 @ 4:46 AM
Ignite Modification Date:
2026-02-20 @ 12:33 PM
Study NCT ID:
NCT01077518
Status:
TERMINATED
Last Update Posted:
2020-03-27
First Post:
2010-02-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphoma, Follicular | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Refractory | View |
| None | Safety | View |
| None | Efficacy | View |
| None | Rituximab refractory | View |
| None | Oncology | View |
| None | Ofatumumab | View |
| None | Bendamustine | View |
| None | Indolent B-cell Non- Hodgkin's Lymphoma Unresponsive | View |
| None | Rituximab | View |
| None | Rituximab-Containing Regimen | View |